Tactile Systems Stock Price, News & Analysis

Tactile Medical (Nasdaq: TCMD) said management will participate in the Piper Sandler 37th Annual Healthcare Conference at the Lotte New York Palace in New York, NY from December 2–4, 2025.

The company will take part in a fireside chat on December 2, 2025 at 8:00 a.m. Central Time. A live audio webcast will be available in the Events & Webcasts section of the company investor relations site (http://investors.tactilemedical.com), and an archive will be posted for replay after the conference.

Tactile Medical (Nasdaq: TCMD) reported Q3 2025 results on November 3, 2025, with total revenue $85.8M (+17% YoY), gross margin 76%, net income $8.2M ($0.36 diluted) and Adjusted EBITDA $14.4M. The company repaid its $24.0M term loan, refinanced its revolver to $40M capacity, and authorized a $25M share repurchase program (expires Nov 3, 2027). Full‑year 2025 guidance was raised to $317M–$321M revenue and $38M–$39.5M adjusted EBITDA. Cash was $66.0M at Sept 30, 2025.

Tactile Medical (Nasdaq: TCMD) presented six-month results from a large randomized controlled trial showing sustained clinical benefits of Flexitouch Plus as first-line therapy for head and neck cancer–related lymphedema.

Key findings: sustained symptom improvement in both study arms, objective swelling reductions at 13 of 19 internal sites with statistically significant decreases at the base of tongue (p=0.008) and arytenoids (p=0.023), and clinician-reported measures favoring Flexitouch Plus. The trial enrolled 236 patients across 10 centers and confirms durability of benefit through six months following earlier two-month data.

Tactile Medical (Nasdaq: TCMD) announced it will release third quarter fiscal 2025 financial results after market close on Monday, November 3, 2025. Management will host a conference call with Q&A on November 3, 2025 at 5:00 p.m. ET.

Investors can join by phone at 877-407-3088 (international 201-389-0927) using access code 13755883, or listen via live webcast at investors.tactilemedical.com. A replay will be available for two weeks at 877-660-6853 (international 201-612-7415), access code 13755883. The webcast will be archived on the investor site.

About the company: Tactile Medical develops at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease to expand access and improve patient quality of life.

Tactile Systems Technology (NASDAQ: TCMD) reported Q2 2025 financial results with total revenue increasing 7.8% year-over-year to $78.9 million. The company achieved a gross margin of 75% and net income of $3.2 million, compared to $4.3 million in Q2 2024.

Key highlights include a 52% increase in airway clearance product sales and a 2% increase in lymphedema product line revenue. The company completed its $30 million share repurchase program, with $16.5 million repurchased in Q2. Management updated 2025 guidance, now expecting full-year revenue of $310-315 million and adjusted EBITDA of $33-35 million.

Tactile Medical (NASDAQ: TCMD), a medical technology company specializing in at-home therapies for chronic conditions, has scheduled its Q2 2025 earnings release for August 4, 2025 after market close.

The company will host a conference call with Q&A at 5:00 p.m. Eastern Time on the same day. Investors can participate via phone (877-407-3088 for domestic, 201-389-0927 for international) using access code 13754589, or through a live webcast on the company's investor relations website.

Tactile Medical focuses on treating conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease, helping patients manage their care at home.

Tactile Medical (NASDAQ: TCMD) presented new clinical data at ASCO 2025 demonstrating the effectiveness of their Flexitouch Plus device in treating lymphedema in head and neck cancer survivors. The study, involving 236 subjects across 10 sites, showed that Flexitouch Plus patients received treatment significantly faster (17.9 days vs 29.8 days for usual care) and had higher treatment initiation rates (94.9% vs 71%). The device demonstrated significant reduction in swelling and improved quality-of-life metrics in three of six sub-scales. The two-month analysis revealed that while both usual care and Flexitouch Plus (APCD) were similarly effective, APCD showed distinct advantages in treatment accessibility and swelling reduction. The company expects six-month results later this year, which could expand commercial payer coverage and improve care access.

Tactile Medical (NASDAQ: TCMD), a medical technology company focused on therapies for chronic disorders, has announced its participation in two major investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3 at 3:20 p.m. CST, followed by a presentation at the Jefferies Global Healthcare Conference in New York on June 4 at 2:35 p.m. EST.

Live audio webcasts of both presentations will be available on the company's investor relations website under the \"Events & Webcasts\" section, with replay options available after the conferences. Tactile Medical specializes in at-home therapies for conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease.

Tactile Systems Technology (NASDAQ: TCMD) reported its Q1 2025 financial results with total revenue increasing 0.3% year-over-year to $61.3 million. The company saw improved gross margins of 74% compared to 71% in Q1 2024, but reported a net loss of $3.0 million versus $2.2 million in Q1 2024. Key highlights include a $10.0 million stock repurchase, expanded launch of Nimbl for lower extremity lymphedema patients, and implementation of a new CRM tool. The company's airway clearance product line sales increased by 22%, while lymphedema product line sales decreased by 3%. Tactile Medical revised its 2025 outlook downward, now expecting full-year revenue of $309-315 million (5-8% growth) and adjusted EBITDA of $32-34 million, compared to previous guidance of $316-322 million revenue and $35-37 million adjusted EBITDA.